1\vo hundred and forty-six patients with signs of acute bacterial conjunctivitis and/or blepharitis were random ised to receive either norftoxacin or chloramphenicol for one week in this double-masked parallel group study. 
Eye (1992) 6, 111-114 the very least, disquieting and bothersome, and more rarely result in sight-threatening complications. The oph thalmologist is limited by available antibacterial agents which may not be ideal due to limited antibacterial spec trum, the presence of resistance, or ocular or systemic side effects, (e.g. gentamicin).l The quinolones are a new class of antibacterial drugs that provide broad-spectrum therapy applicable to ophthalmic infections. 2 Quinolones inhibit bacterial DNA gyrase. This is a novel antibacterial mech anism, which is thought to be less likely to generate resistance. 3 Norfloxacin is a quinolone derivative with a wide spec trum of antibacterial activity. Its spectrum covers Gram positive and Gram-negative bacteria, including Pseudo monas aeruginosa.3.4 Given orally, norfloxacin was effective for the treatment of adult gonococcal keratocon junctivitis and without undesirable toxicity. s In vitro, nor floxacin provides potent and wide spectrum antibacterial action ocular pathogens. 6 Given the wide spectrum of activity, and positive systemic efficacy and safety profile, and the reduced likelihood for cross-resistance, we wished to evaluate the topical use of norfloxacin in treating infec tions of the conjunctiva and lids.
SUBJECTS AND METHODS
This was a randomised, double-masked, parallel-group comparison of 0.3% norfloxacin solution, preserved with 0.0025% benzalkonium chloride and commercially avail able 0.5% chloramphenicol, preserved with 0.002% phe nylmercuric acetate (Chloromycetin®, Parke-Davis). As commercially available chloramphenicol requires refrig eration, both treatments were refrigerated until dispensed to protect the masking of treatments.
For inclusion in the study, patients were required to have a clinical diagnosis of acute conjunctivitis or blepha roconjunctivitis. Patients with blepharitis were also admit ted to the study, but only if the infection was acute. All patients were required to have conjunctival hyperemia, and at least one of the following: purulent exudates; crust ing on eyelids; thickened, red lid margins; or loss of some cilia. Excluded were patients with: symptoms of longer than seven days duration; treatment with ophthalmic ste roids or antibiotics in the previous two weeks; signs or symptoms suspected to be caused by a viral, chlamydial or fungal infection, or allergic inflammation; concomitant systemic antimicrobial therapy or other ophthalmic anti microbial therapy; history of allergy to quinolone deriva tives or to chloramphenicol; and women who were pregnant, nursing, or of childbearing potential and not using adequate contraceptive measures.
All patients gave informed consent. Prior to treatment, the investigators measured visual acuity, evaluated symp toms, and conducted an external ocular examination. A specimen for bacteriological evaluation was obtained from the conjunctiva (or lid margin for patients with ble pharitis alone) with a moistened calcium alginate swab.
The swab was placed in a Calgon-Ringer solution con taining 1 % sodium metaphosphate. At the bacteriology laboratory, the specimen was plated onto both blood and chocolate agar plates, and incubated for 48 hours in 
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Clinical outcome was scored at the end of therapy as cured (signs and symptoms of infection clear), improved (signs and/or symptoms still present but of less severity than at pretreatment), unimproved (no change in signs and symptoms from pretreatment), or worsened (signs and symptoms increased from pretreatment). To be considered evaluable, a patient was required to have a positive culture prior to treatment, and both a bacteriological and clinical outcome recorded.
Comparisons between treatment groups in bacteriolog ical and clinical efficacy were performed using the Man tel-Haenszel procedure without continuity correction, stratifying on investigator.
10, 11 Treatment -by-investigator interaction was assessed by testing the homogeneity of the odds ratio. 
RESULTS
Two hundred and forty-six patients were enrolled into the study. One hundred and sixty-nine of these patients had cultures with no organism isolated, insufficient organisms isolated, or did not have both pre-treatment and post treatment cultures performed. These patients were con sidered non-evaluable for the analysis of bacteriological outcome.
As shown in Table I , the patients represented a large age range, including 13 patients under 18 years of age (nine in the norfloxacin group and four in the chloramphenicol group). There were more males in the norfloxacin treat ment group, and more females in the chloramphenicol treatment group. This difference was statistically signifi- Approximately half the patients received bilateral treat ment, half had a diagnosis of conjunctivitis, and half the diagnosis of blepharoconjunctivitis. Only seven patients were admitted with acute blepharitis. Two patients, one with keratoconjunctivitis and one with a corneal ulcer, were not included in the analysis of efficacy.
NORFLOXACIN VS CHLORAMPHENICOL
The clinical outcome of treatment is shown in Table II. Irrespective of bacteriological status, most patients in both treatment groups were either clinically cured or improved.
In the total study population, exclusive of those patients for whom no clinical outcome was available, 92% of the norfloxacin treatment group and 93% of the chloramphen icol treatment group received clinical benefit from the treatment. In the evaluable patient population, 100% of the norfloxacin treatment group and 97% of the chlo ramphenicol treatment group received clinical benefit from study participation. Ninety-five per cent confidence intervals for cured, and cured or improved, are shown in Table II . Based upon the total number of patients enrolled, Shown in Table III is the clinical outcome, stratified by organism. All patients were judged as cured or improved, irrespective of organism. The observation of improvement or cure in all patients, irrespective of treatment group or organism precludes any differences between group, or organism or whether, indeed, the infection was bacterial.
Shown in Table IV Five patients were withdrawn from further study par ticipation due to a presumed drug-related adverse experi ence. One norftoxacin-treated patient was withdrawn due to a mild burning upon instillation, and a second due to a mild headache. Two chloramphenicol-treated patients were withdrawn due to an ocular reaction, and one chlo ramphenicol-treated patient withdrawn due to eye pain.
DISCUSSION
We found norfloxacin to be effective and relatively safe We observed norfloxacin to be of similar efficacy and However, the public health risks of individuals with pur ulent exudates which may be communicable, as well as the small but real threat of a sight-threatening complication, tend to outweigh the risks of treatment.
It is difficult to assess the natural history of presumed bacterial conjunctivitis in our study, as both groups of patients received active treatments. In a previously reported paediatric study, where some children did not receive antibacterial treatment, the disease was self-lim
iting, yet the severity and duration of the signs and symp toms of infection were less in the group receiving antibacterial treatment. 18 While we cannot determine from this study the unequivocal efficacy of norftoxacin in treat ing external ocular bacterial infections, norftoxacin was similar to chloramphenicol in that the majority of patients in this study experienced clinical and microbiological res olution of their acute symptoms and signs.
In this study, norftoxacin was effective in controlling the observed bacteria. However, no patients in either treat ment group had positive cultures for Pseudomonas, an organism of concern with respect to spectrum of antibac terial activity. Similary, no development of tolerance was observed in this study of large sample size, albeit of rela tively short treatment duration. Finally, no significant,
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drug-related ocular or systemic adverse events were observed in either treatment group.
